# SBC Medical Group Holdings Incorporated (SBC) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Health Care Equipment & Supplies. Price $4.12, market value $424 million.

## Valuation
- **P/E (trailing): 8.6×** (5-yr avg 15.3×, 3-yr avg 15.3×). SBC Medical Group Holdings Incorporated trades at 8.6× trailing earnings, well below its own five-year average of 15.3×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 7.6×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 1.83**. A PEG of 1.83 is in the range usually read as fairly priced for its growth.
- **Price / sales: 2.4×**. Each dollar of revenue is priced at 2.4×.
- **Price / book: 1.6×**. The shares trade at 1.6× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 4.4×**. Enterprise value is 4.4× operating earnings before depreciation, the multiple that ignores how the company is financed; below 8× is inexpensive for most sectors.
- **Free-cash-flow yield: 14.6%** (5-yr avg 4.3%). Free cash flow equals 14.6% of the market value, above its five-year average of 4.3%, so the shares are cheaper on cash than they have usually been. Above 5% is generally attractive.
- **Earnings yield: 11.7%**. The inverse of the P/E: 11.7% of the price is earned each year.

## Profitability
- **Gross margin: 71.9%**. SBC Medical Group Holdings Incorporated keeps 71.9% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 37.3%**. 37.3% of revenue is left after running the business, an exceptional level.
- **Net margin: 29.4%**. 29.4% of each dollar of sales reaches the bottom line.
- **Return on equity: 20.5%**. 20.5% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on invested capital: 40.5%**. Return on all capital, debt included, is 40.5%: comfortably above what that capital costs.
- **Return on assets: 12.9%**. Each dollar of assets produces 12.9% of profit.

## Growth
- **Revenue growth (1 yr): -15.5%**. Revenue fell 15.5% over the last year.
- **EPS growth (1 yr): 4.2%**. Earnings per share rose 4.2%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.17**. Debt is 0.17 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. SBC Medical Group Holdings Incorporated holds more cash than debt.
- **Altman Z-score: 4.13**. A Z-score of 4.13 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. SBC Medical Group Holdings Incorporated does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (4 analysts). 4 analysts cover SBC Medical Group Holdings Incorporated; the consensus is strong_buy, with an average price target of $8.75 (+112% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 1.2%** (YTD -4.4%, 3-mo 36.9%). The shares are up 1.2% over twelve months including dividends.
- **From 52-week high: -17.6%** (48.2% above the low). Trading 18% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 63**. An RSI of 63 is neutral.
- **Beta (1 yr): 0.64** (volatility 59%). Beta of 0.64 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=SBC · Page: https://foliofundamentals.com/stocks/sbc

Not investment advice.